What is Syntach?
Headquartered in Lund, Sweden, Syntach AB operates at the intersection of advanced engineering and clinical cardiology. The company is dedicated to establishing an entirely new class of cardiac support devices designed to improve patient outcomes for those suffering from chronic heart failure. By focusing on innovative mechanical circulatory support, Syntach aims to bridge the gap between traditional pharmacological interventions and invasive surgical procedures, positioning itself as a high-growth entity within the medical technology sector.
How much funding has Syntach raised?
Syntach has raised a total of $16.2M across 1 funding round:
Private Equity
$16.2M
Private Equity (2023): $16.2M with participation from The European Innovation Council
Key Investors in Syntach
The European Innovation Council
The European Innovation Council is a prominent funding body that supports breakthrough technologies and high-potential startups, focusing on scaling deep-tech innovations across the European Union.
What's next for Syntach?
The recent infusion of capital provides Syntach with the necessary runway to advance its core technology through rigorous clinical validation and regulatory milestones. As the company transitions from early-stage development to more mature operational phases, the focus will likely shift toward scaling manufacturing capabilities and expanding its intellectual property portfolio. Given the current market trajectory for cardiovascular health solutions, Syntach is poised to leverage this strategic backing to solidify its competitive advantage and potentially disrupt the standard of care for heart failure patients globally.
See full Syntach company page
